GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: Business Wire
ultraRapid testing addresses the underutilization of testing in the NICU and can lead to more than $15K in healthcare savings per child GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced ultraRapid Whole Genome Sequencing, offering accelerated and comprehensive genomic insights for neonatal and pediatric patients in the NICU and PICU in as soon as 2 days.ultraRapid genome testing delivers a faster diagnosis, providing clinically actionable results and the opportunity to shorten a NICU stay. Genetic diseases are the most common identifiable cause of infant death, and for every baby who fails to receive a genetic diagnosis, their NICU stay is likely to be 15 to 20 days longer.1,2 Additionally, ultraRapid genomic sequencing can drive increased healthcare savings by reducing unnecessary medical treatments and accelerating answers for patients and providers, transforming care when every mome
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- GeneDx (NASDAQ:WGS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $160.00 to $170.00. They now have a "buy" rating on the stock.MarketBeat
- GeneDx (NASDAQ:WGS) was given a new $155.00 price target on by analysts at Wells Fargo & Company.MarketBeat
- JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the YearBusiness Wire
- GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Be 40% Below Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
- GeneDx (NASDAQ:WGS) had its price target raised by analysts at BTIG Research from $165.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
WGS
Earnings
- 10/28/25 - Beat
WGS
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/11/25 - Form 4
- WGS's page on the SEC website